We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pharmacological evaluation of embelin - chitosan nanoparticles as an antidiabetic agent.
- Authors
Maanvizhi, Saba; Radhakrishnan, Narayanaswamy; Krishnan, Chitra; Gnanamani, Arumugam
- Abstract
Embelin has been reported to possess variety of pharmacological activities such as androgenic antagonists, antiangiogenic, antibacterial, anticancer, anticonvulsant, antidiabetic, antidepressant, antihelmintic, antifertility, antihyperlipidemic, anti-inflammatory, antimalarial, antimitotic, antiobesity and antioxidant properties. The current research work aimed to study the hypoglycemic effect of embelin-chitosan nanoparticles (ECNPs) diabetic rats provoked by streptozotocin (STZ). Embelin nanoparticles (ENPs) were created by combining chitosan, a natural biopolymer, and glutaric acid, a new cross-linker. STZ 50 mg/kg was given intravenously into Sprague-Dawley rats weighing 250–300 g (75–90 days) to induce experimental diabetes. The antidiabetic efficacy of orally administered ECNPs in diabetic rats developed by STZ was investigated, as well as histological examination. When compared to diabetic control rats, ECNPs (25 mg/kg body weight and 50 mg kg body weight) and standard glibenclamide (10 mg/kg body weight) treated rodents exhibited a remarkable drop in glucose contents. Furthermore, histological research showed that ECNPs-treated rats were harmless up to amount of 25 mg/kg bwt. Thus current investigation reveals that ECNPs have antidiabetic potential and may be beneficial in treating hyperglycemia in people.
- Subjects
HYPOGLYCEMIC agents; GLYCEMIC control; LABORATORY rats; SPRAGUE Dawley rats; CHITOSAN; NANOPARTICLES
- Publication
Indian Journal of Pharmacology, 2022, Vol 54, Issue 2, p126
- ISSN
0253-7613
- Publication type
Article
- DOI
10.4103/ijp.ijp_47_20